Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
The PSO-1 (Pritsel Snaipersky Optichesky, "Optical Sniper Sight") is a Russian scope with 4x magnification compared to the iron sights. The PSO-1 (4x) falls in the Optics Category of the Weapon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback